November 15, 2006Open Access

Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life. (ClinicalTrials.gov number, NCT00211120 ClinicalTrials.gov.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Singh et al. (Wed,) studied this question.

synapsesocial.com/papers/69d733a13f2a6ac123b8a559 https://doi.org/https://doi.org/10.1056/nejmoa065485

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Group Sequential Methods with Applications to Clinical Trials1999 · 1,351 citations
2A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation1999 · 15,136 citations
3The MOS 36-Item Short-Form Health Survey (SF-36)1993 · 6,673 citations
4On the receiving end—II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy1983 · 158 citations
5Anemia treatment in the pre-ESRD period and associated mortality in elderly patients2002 · 101 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo